Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

28.0%

54 terminated/withdrawn out of 193 trials

Success Rate

68.8%

-17.7% vs industry average

Late-Stage Pipeline

47%

90 trials in Phase 3/4

Results Transparency

74%

88 of 119 completed trials have results

Key Signals

1 recruiting88 with results36 terminated18 withdrawn

Enrollment Performance

Analytics

Phase 4

50(27.0%)

Phase 2

47(25.4%)

Phase 3

40(21.6%)

Phase 1

27(14.6%)

N/A

15(8.1%)

Early Phase 1

6(3.2%)

185Total

Phase 4(50)

Phase 2(47)

Phase 3(40)

Phase 1(27)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (193)

Showing 20 of 193 trials

NCT02523092Phase 4Terminated

Use of CXCL9 as a Biomarker of Acthar Efficacy

Role: collaborator

NCT03020875Phase 4Completed

IV vs Oral Acetaminophen in Spine Fusion Perioperative Care

Role: collaborator

NCT02298491Phase 4Completed

Treatment of CNS Sarcoidosis With H.P. Acthar Gel

Role: collaborator

NCT04996667Phase 2Withdrawn

Effect of iNO in Patients With Submassive and Massive PE

Role: collaborator

NCT02541955Phase 4Completed

Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Role: collaborator

NCT01172691Phase 2Completed

Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts

Role: collaborator

NCT02931175Phase 2Completed

ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

Role: collaborator

NCT03023449Phase 2Active Not Recruiting

Diffuse Optical Monitoring With Inhaled Nitric Oxide

Role: collaborator

NCT04216927Phase 3Recruiting

NO During CPB in Neonates to Reduce Risk of AKI

Role: collaborator

NCT04986605Phase 2Not Yet Recruiting

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis

Role: collaborator

NCT01950234Phase 2Terminated

ACTH in Progressive Forms of MS

Role: collaborator

NCT03576885Phase 1Terminated

Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia

Role: collaborator

NCT02151877Not ApplicableCompleted

Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass

Role: collaborator

NCT02245841Phase 4Completed

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

Role: collaborator

NCT05052385Completed

ECP Combination Study

Role: collaborator

NCT06249633Early Phase 1Not Yet Recruiting

Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

Role: collaborator

NCT03511625Phase 3Unknown

The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis

Role: collaborator

NCT02725177Not ApplicableCompleted

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Role: collaborator

NCT03465111Phase 2Unknown

A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis

Role: collaborator

NCT02030028Not ApplicableCompleted

ACTH Gel Therapy in Rheumatoid Arthritis

Role: collaborator